ZVRA Zevra Therapeutics, Inc.
Healthcare$10.32+2.89%ClosedMarket Cap: $610.1M
As of 2026-05-26
Valuation
P/E (TTM)
6.83
PEG
0.04
P/B
2.85
P/S
4.85
EV/EBITDA
4.69
DCF Value
$-40.12
FCF Yield
2.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
85.5%
Operating Margin
-39.9%
Net Margin
101.6%
ROE
81.3%
ROA
44.6%
ROIC
-19.6%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $36.2M | 93.7% | $8.8M | $37.9M | $— | — |
| Q4 null | $34.1M | 95.5% | $9.3M | $12.2M | $— | — |
| FY null | $106.5M | 84.5% | $-4.2M | $83.2M | $— | — |
| Q3 null | $26.1M | 94.0% | $4.1M | $-544.0K | $— | — |
| Q2 null | $25.9M | 52.2% | $-71.0M | $74.7M | $— | — |
| Q1 null | $20.4M | 93.4% | $-5.4M | $-3.1M | $— | — |
| Q4 null | $12.0M | 88.7% | $-15.4M | $-35.7M | $— | — |
| FY null | $23.6M | 68.6% | $-87.0M | $-105.5M | $— | — |
| Q3 null | $3.7M | 37.7% | $-27.3M | $-33.2M | $— | — |
| Q2 null | $4.4M | 19.7% | $-23.8M | $-19.9M | $— | — |
| Q1 null | $3.4M | 4.7% | $-20.5M | $-16.6M | $— | — |
| Q4 2023 | $13.2M | 78.9% | $-14.7M | $-15.2M | $-0.40 | — |